Application of beta-nicotinamide mononucleotide and / or salt thereof in preparation of exogenous myelosuppression injury protective agent
By using β-nicotinamide single nucleotide (NMN) to regulate the bone marrow microenvironment, the problems of large individual differences, high costs and many adverse reactions in the treatment of exogenous myelosuppression injury in the prior art are solved, and bone marrow suppression injury is achieved Effective prevention and treatment have significantly improved the bone marrow hematopoietic function.
Patent Information
- Application Number
- CN202411162022.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-22
- Publication Date
- 2024-11-08
AI Technical Summary
The prior art has problems such as large individual differences, high treatment costs and many adverse reactions in the treatment of exogenous myelosuppression injury, and it is difficult to meet the effective treatment of pneumocythopenia caused by myelosuppression.
β-nicotinamide single nucleotide (NMN) is used as a protective agent for the preparation of exogenous myelosuppression injury. By regulating the bone marrow microenvironment, anti-inflammatory and oxidative stress injuries, it can improve the level of nucleated cells of the bone marrow and secretion of hematopoietic factors, and promote bone marrow. Recover hematopoietic function.
NMN significantly improves the safety, effectiveness and economicality of disease prevention and treatment, can effectively prevent and treat myelosuppression damage caused by radiation exposure and toxicity of chemotherapy drugs, comprehensively improve white blood cell, red blood cell and platelet counts, and significantly reduce hematopoietic function damage.
Smart Images

Figure BDA0005006720540000041 
Figure BDA0005006720540000051
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of medical treatment and health technology, and particularly relates to the application of β-nicotinamide mononucleotide and / or its salt in preparing an exogenous bone marrow suppression injury protective agent. Background Art
[0002] The bone marrow microenvironment is the place where immune cells grow and mature. It is very sensitive to various physical, chemical and metabolic harmful factors in the body, and plays a key role in maintaining the homeostasis of the immune system. Once the bone marrow microenvironment is disturbed, local tissue inflammation will be induced, and the immune response will be further triggered. The repeated occurrence of this phenomenon will affect the immune function. Radiation exposure and chemotherapeutic drug toxicity are two common exogenous factors that cause bone marrow suppression. At present, clinically, cytokine therapy or immunomodulators are mainly used to relieve symptoms of exogenous bone marrow suppression damage, but there are generally problems such as large individual differences, high treatment costs, and many additional adverse reactions. For pancytopenia caused by bone marrow suppression, cytokine therapy needs to use EPO (erythropoietin, erythrocyte stimulating factor), IL-11 (platelet stimulating factor), G-CSF (granulocyte colony stimulating factor), GM-CSF (granulocyte / macrophage colony stimulating factor), etc. to solve different types of blood cell reduction problems. Therefore, patients need to use multiple types of drugs at the same time, and are prone to fever and muscle and joint pain, which greatly limits the clinical effect. There are also some Chinese patent medicines that use leukopenia, thrombocytopenia or anemia as indications, but few are targeted at pancytopenia caused by bone marrow suppression, and the treatment methods do not fully conform to the etiology and pathogenesis of bone marrow suppression and the physical characteristics of patients, making it difficult to meet clinical use. In view of the current unmet clinical needs, it is of great significance to develop new safe, efficient and economical bone marrow suppression prevention and treatment technologies.
[0003] β-Nicotinamide mononucleotide (nicotinamidemononucleotide), referred to as NMN, is a vitamin B derivative composed of nicotinamide, ribose and phosphate groups. It is found in milk, meat, and fruits and vegetables such as broccoli and cabbage. It is also a key intermediate in the salvage synthesis pathway of coenzyme I (nicotinamide adenine dinucleotide, NAD+) in the redox reaction in the human body. It has a wide range of physiological activities that are beneficial to health, such as maintaining intestinal health, delaying aging, protecting against metabolic diseases, cardiovascular and cerebrovascular diseases, and neurodegenerative diseases. It is known as a "longevity drug" and has received high attention. However, the mechanism by which NMN regulates the bone marrow microenvironment is still unclear, and there are no reports on the application of NMN in the prevention and treatment of bone marrow suppression. Summary of the invention
[0004] The purpose of the present invention is to provide an application of human endogenous active substance β-nicotinamide mononucleotide and / or its salt (NMN) in the prevention and / or treatment of bone marrow suppression damage, specifically the application of β-nicotinamide mononucleotide and / or its salt to prepare an exogenous bone marrow suppression damage protective agent.
[0005] Application of β-nicotinamide mononucleotide and / or its salt in preparing exogenous bone marrow suppression damage protective agent.
[0006] Furthermore, the bone marrow suppression injury is exogenous bone marrow suppression injury caused by radiation exposure and / or drug toxicity and side effects. Among them, the exogenous bone marrow suppression injury verified by the experiment of the present invention is exogenous bone marrow suppression injury caused by X-ray irradiation and tumor chemotherapy drug cisplatin.
[0007] Furthermore, the application of NMN in the prevention and treatment of bone marrow suppression damage is to prepare NMN and other substances into various dosage forms of therapeutic drugs, preventive drugs, health products, nutritional supplements, and special medical purpose formula foods, etc., and the preparations used are in the form of oral preparations or injections.
[0008] Furthermore, the therapeutic drugs, preventive drugs, health products, nutritional supplements, and special medical purpose formula foods used in the treatment and prevention of bone marrow suppression damage by using NMN do not contain other active ingredients against bone marrow suppression damage except NMN.
[0009] The application of NMN in the prevention and treatment of bone marrow suppression damage is specifically manifested in that it can effectively increase the level of bone marrow nucleated cells and the secretion of hematopoietic factors while inhibiting inflammation and oxidative stress damage, thereby promoting the recovery of bone marrow hematopoietic function, maintaining stable white blood cell, red blood cell and platelet count levels, and exerting a comprehensive protective effect on multiple pathways of bone marrow suppression caused by exogenous factors such as radiation and chemotherapy.
[0010] The technical solution provided by the present invention includes at least the following beneficial effects:
[0011] (1) The use of β-nicotinamide mononucleotide and / or its salts in the preparation of exogenous bone marrow suppression injury protective agents provides a path for preparing exogenous bone marrow suppression injury prevention and treatment drugs, and experimental data verify that NMN can regulate the bone marrow microenvironment and resist bone marrow suppression, especially for exogenous bone marrow suppression damage caused by radiation exposure and / or drug toxicity and side effects. It shows good preventive and therapeutic effects, providing a new idea for the prevention and / or treatment of the above-mentioned bone marrow suppression damage.
[0012] (2) NMN in the present invention is an endogenous active substance in the human body, which has the advantages of high efficiency and low toxicity in the prevention and treatment of exogenous bone marrow suppression damage. It can solve the technical defects of existing anti-bone marrow suppression damage measures, which generally require the use of multiple types of drugs to solve different types of hematopoiesis and are accompanied by many additional adverse reactions. It can significantly improve the safety, effectiveness, convenience and economy of disease prevention and treatment, and has broad application prospects in the preparation of medicines, health products, nutritional supplements or special medical formula foods for the prevention and / or treatment of exogenous bone marrow suppression and its induced pancytopenia.
[0013] Obviously, according to the above contents of the present invention, in accordance with common technical knowledge and customary means in the art, without departing from the above basic technical ideas of the present invention, other various forms of modification, replacement or change may be made. DETAILED DESCRIPTION
[0014] The above contents of the present invention are further described in detail below through specific implementation methods in the form of embodiments. However, this should not be understood as the scope of the above subject matter of the present invention being limited to the following examples. All technologies realized based on the above contents of the present invention belong to the scope of the present invention.
[0015] The technical scheme and technical effects of the present invention are demonstrated below through experimental example data.
[0016] The materials and instruments used in the present invention are all known products, which are obtained by purchasing commercially available products.
[0017] The experimental animals were healthy C57BL / 6J female mice, 7 weeks old, weighing (20±0.2) g, provided by Shandong Jinan Pengyue Experimental Animal Breeding Co., Ltd., license number: SCXK(Lu)20220006. The experimental animals were kept in a room with an average temperature of 21℃-23℃, a relative humidity of 40%-70%, and a 12-hour light / dark cycle under specific non-pathogenic conditions. The experiment began after at least one week of adaptive feeding. All experimental animals were given normal diet and drinking water during the experiment.
[0018] Experimental Example 1: Effect of NMN on bone marrow suppression damage in mice induced by X-ray irradiation
[0019] 1.1 Drug administration and irradiation treatment
[0020] The experimental mice that had undergone adaptive feeding were randomly divided into three groups, namely the normal group, the model control group and the NMN treatment group, with 10 animals in each group. Among them, the animals in the normal group did not receive any drug treatment during the experiment; the NMN treatment group was given NMN (including excipients) by oral gavage at a dose of 20 mg / kg once a day, and the model control group was given the same amount of excipients as the drug treatment group in the same way; after 14 consecutive days of treatment, all animals in the drug treatment group and the model control group received a one-time whole-body X-ray irradiation, with the specific parameters as follows: source-skin distance 100 cm, irradiation rate 2.095 Gy / min, total dose 5.5 Gy.
[0021] 1.2 Sample collection and indicator determination
[0022] On the 7th day after irradiation, blood was collected from animals in each group to prepare plasma and serum samples, and routine blood tests were performed using a blood cell counter, including red blood cell (RBC), white blood cell (WBC), platelet (PLT) counts and hemoglobin (HGB) content; hematopoietic factors in plasma, inflammatory factors and oxidative stress factors in serum were detected using ELISA kits; at the same time, the right femur was dissected and bone marrow mononuclear cell (BMNC) suspension was prepared, and BMNC counts were performed using an inverted fluorescence microscope.
[0023] All experimental data were expressed as (mean ± standard deviation); t-test was used for comparison between two groups, and one-way analysis of variance was used for comparison between multiple groups. p<0.05 indicated statistically significant differences.
[0024] 1.3 Experimental Results
[0025] The results of blood routine and BMNC counts of animals in each group are shown in Table 1. Taking the normal group as the control, the peripheral blood HGB content and WBC, RBC, PLT and BMNC counts of animals in the model group were significantly reduced (p<0.01), indicating that X-ray irradiation clearly caused bone marrow suppression in mice, and the mouse model of exogenous irradiation-induced bone marrow suppression was successfully established; compared with the model group, the NMN treatment group can significantly increase WBC, RBC, PLT, HGB and BMNC in peripheral blood (p<0.05).
[0026] The results showed that NMN can effectively inhibit X-ray-induced bone marrow damage in mice, inhibit pancytopenia caused by bone marrow damage, comprehensively increase peripheral blood HGB content and WBC, RBC, PLT and BMNC count levels, and promote the recovery of bone marrow suppression damage caused by radiation.
[0027] Table 1: Peripheral blood routine and BMNC test results of mice treated with X-ray irradiation (n=10)
[0028]
[0029] Note: Compared with the normal group, * p<0.05, ** p<0.01, *** p<0.001; compared with the model group, # p<0.05, ## p<0.01, ### p<0.001.
[0030] Example 2: NMN inhibits bone marrow damage in mice induced by the tumor chemotherapy drug cisplatin
[0031] 2.1 Construction of chemotherapy drug injury model and grouping treatment
[0032] The experimental mice that had undergone adaptive feeding were randomly divided into 3 groups, namely the normal group, the model group and the NMN treatment group, with 10 animals in each group. Among them, the NMN treatment group was given NMN (including excipients) by oral gavage at a dose of 20 mg / kg once a day, and the model group was given the same amount of excipients as the drug treatment group in the same way; after 14 consecutive days of treatment, the animals in the model group and the NMN treatment group were given cisplatin by tail vein injection, with a dosing schedule of 5 mg / kg / d, once a day, for 3 consecutive days; the animals in the normal group did not receive any drug treatment during the experiment, and were given the same amount of blank solvent / excipients in the same way.
[0033] 2.2 Sample collection and indicator determination
[0034] 24 hours after the last injection of cisplatin, blood was collected from animals in each group to prepare plasma and serum samples, and routine blood tests were performed using a hematology counter, including RBC, WBC, PLT counts and HGB content; hematopoietic factors in plasma, inflammatory factors and oxidative stress factors in serum were detected using ELISA kits; at the same time, the right femur was dissected and BMNC suspension was prepared, and the BMNC count was determined using an inverted fluorescence microscope.
[0035] All experimental data were expressed as (mean ± standard deviation); t-test was used for comparison between two groups, and one-way analysis of variance was used for comparison between multiple groups. p<0.05 indicated statistically significant differences.
[0036] 2.3 Experimental Results
[0037] The results of blood routine and BMNC counts of animals in each group are shown in Table 2. Taking the normal group as the control, it can be seen that the peripheral blood HGB content and WBC, RBC, PLT and BMNC counts of animals in the model group were comprehensively reduced (p<0.05), especially the HGB content and BMNC count levels were highly significantly reduced (p<0.001), indicating that the tumor chemotherapy drug cisplatin clearly caused bone marrow suppression in mice, and the mouse model of bone marrow suppression caused by exogenous drug toxicity was successfully established; compared with the model group, the WBC, RBC, PLT, HGB and BMNC in the NMN treatment group were significantly increased (p<0.05), especially the PLT count level was significantly increased to close to that of the normal group (p<0.001).
[0038] The results showed that NMN can effectively inhibit the toxicity of chemotherapy drugs and the bone marrow damage in mice, inhibit the occurrence of pancytopenia, comprehensively increase the peripheral blood HGB content and the WBC, RBC, PLT and BMNC count levels, and promote the recovery of cisplatin bone marrow suppression damage caused by chemotherapy drugs.
[0039] Table 2: Peripheral blood routine and BMNC detection results of mice treated with cisplatin (n=10)
[0040]
[0041] Note: Compared with the normal group, * p<0.05, ** p<0.01, *** p<0.001; compared with the model group, # p<0.05, ## p<0.01, ### p<0.001.
[0042] The experimental data of Examples 1 and 2 above show that NMN can effectively inhibit exogenous bone marrow damage, including exogenous bone marrow damage caused by X-ray irradiation, toxicity of tumor chemotherapy drug cisplatin, etc. After using NMN, it can effectively treat and inhibit the above-mentioned exogenous bone marrow damage, effectively regulate the bone marrow microenvironment, regulate the secretion of hematopoietic cytokines such as erythropoietin and thrombopoietin, inhibit oxidative stress damage, thereby inhibiting the decrease in the count of white blood cells, red blood cells, platelets, hemoglobin and bone marrow nucleated cells in peripheral blood cells caused by exogenous factors, comprehensively improve the clinical symptoms of pancytopenia caused by bone marrow suppression, and significantly reduce the degree of hematopoietic function damage.
[0043] Therefore, β-nicotinamide mononucleotide and / or its salt can be used as a protective agent for treating exogenous bone marrow suppression damage, which can be used to solve the technical defects of the prior art that multiple types of drugs need to be used simultaneously to solve different types of hematopoiesis and many additional adverse reactions are associated with it, and has broad application prospects in the preparation of medicines, health products, nutritional supplements or special medical formula foods for preventing and / or treating exogenous bone marrow suppression damage and pancytopenia caused by it.
[0044] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. Use of β-nicotinamide mononucleotide and / or its salt in the preparation of an exogenous bone marrow suppression injury protective agent, characterized in that The exogenous bone marrow suppression injury is exogenous bone marrow suppression injury caused by X-ray irradiation and tumor chemotherapy drug cisplatin.
2. The use according to claim 1, characterized in that: The β-nicotinamide mononucleotide and / or its salt is used to prepare medicines, health products, nutritional supplements, and formula foods for medical purposes.
3. The use according to claim 2, characterized in that: The medicine, health product, nutritional supplement, and formula food for medical use, except for β-nicotinamide mononucleotide and / or its salt, does not contain other active ingredients with the effect of preventing and treating bone marrow suppression damage.
4. The use according to claim 2 or 3, characterized in that: The application preparation form of the medicine, health care product, nutritional supplement and medical formula food is oral preparation or injection.
